Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0ARJSB
ADC Name	CN105828840B ADC-126
Synonyms	CN105828840B ADC-126 Click to Show/Hide
Organization	Genentech Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Adult acute myeloid leukemia [ICD11:2A60] Investigative
Drug-to-Antibody Ratio	1.8
	3D MOL	2D MOL
Antibody Name	CN105828840B_ADC-126 antibody
Antigen Name	Mucin-16 (MUC16)		Antigen Info
Payload Name	Undisclosed
Linker Name	CN105828840B_ADC-126 linker

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≍ 44	%	CVCL_0002	Adult acute myeloid leukemia
Tumor Growth Inhibition value (TGI)	≍ 55.2	%	CVCL_0465	Ovarian serous adenocarcinoma
Tumor Growth Inhibition value (TGI)	≍ 78.4	%	CVCL_0465	Ovarian serous adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 44.00% (Day 13)	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 55.20% (Day 21)	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 78.40% (Day 21)	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

References

Ref 1	1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.